Product: TRAF3 Antibody
Catalog: AF5380
Description: Rabbit polyclonal antibody to TRAF3
Application: WB IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 68 kDa, 55 kDa; 64kD(Calculated).
Uniprot: Q13114
RRID: AB_2837865

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(92%), Xenopus(92%)
Clonality:
Polyclonal
Specificity:
TRAF3 Antibody detects endogenous levels of total TRAF3.
RRID:
AB_2837865
Cite Format: Affinity Biosciences Cat# AF5380, RRID:AB_2837865.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CAP 1; CAP-1; CAP1; CD40 associated protein 1; CD40 binding protein; CD40 bp; CD40 receptor associated factor 1; CD40 receptor-associated factor 1; CD40-binding protein; CD40BP; CRAF 1; CRAF1; IIAE5; LAP 1; LAP1; LMP1 associated protein; LMP1-associated protein 1; MIPT3; TNF receptor associated factor 3; TNF receptor-associated factor 3; TRAF 3; Traf3; TRAF3_HUMAN;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Description:
TRAF1 and TRAF2 (for TNF receptor-associated factors 1 and 2, respectively). Both function to form heterodimeric complexes and associate with the cytoplasmic domain of TNF-R2
Sequence:
MESSKKMDSPGALQTNPPLKLHTDRSAGTPVFVPEQGGYKEKFVKTVEDKYKCEKCHLVLCSPKQTECGHRFCESCMAALLSSSSPKCTACQESIVKDKVFKDNCCKREILALQIYCRNESRGCAEQLMLGHLLVHLKNDCHFEELPCVRPDCKEKVLRKDLRDHVEKACKYREATCSHCKSQVPMIALQKHEDTDCPCVVVSCPHKCSVQTLLRSELSAHLSECVNAPSTCSFKRYGCVFQGTNQQIKAHEASSAVQHVNLLKEWSNSLEKKVSLLQNESVEKNKSIQSLHNQICSFEIEIERQKEMLRNNESKILHLQRVIDSQAEKLKELDKEIRPFRQNWEEADSMKSSVESLQNRVTELESVDKSAGQVARNTGLLESQLSRHDQMLSVHDIRLADMDLRFQVLETASYNGVLIWKIRDYKRRKQEAVMGKTLSLYSQPFYTGYFGYKMCARVYLNGDGMGKGTHLSLFFVIMRGEYDALLPWPFKQKVTLMLMDQGSSRRHLGDAFKPDPNSSSFKKPTGEMNIASGCPVFVAQTVLENGTYIKDDTIFIKVIVDTSDLPDP

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Xenopus
92
Chicken
92
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q13114 As Substrate

Site PTM Type Enzyme
S9 Phosphorylation
T29 Phosphorylation
Y39 Phosphorylation
K138 Methylation
K168 Ubiquitination
S275 Phosphorylation
S281 Phosphorylation
K329 Ubiquitination
K335 Ubiquitination
S349 Phosphorylation
K351 Ubiquitination
S356 Phosphorylation
K369 Ubiquitination
K513 Ubiquitination
K557 Ubiquitination

Research Backgrounds

Function:

Regulates pathways leading to the activation of NF-kappa-B and MAP kinases, and plays a central role in the regulation of B-cell survival. Part of signaling pathways leading to the production of cytokines and interferon. Required for normal antibody isotype switching from IgM to IgG. Plays a role T-cell dependent immune responses. Plays a role in the regulation of antiviral responses. Is an essential constituent of several E3 ubiquitin-protein ligase complexes. May have E3 ubiquitin-protein ligase activity and promote 'Lys-63'-linked ubiquitination of target proteins. Inhibits activation of NF-kappa-B in response to LTBR stimulation. Inhibits TRAF2-mediated activation of NF-kappa-B. Down-regulates proteolytic processing of NFKB2, and thereby inhibits non-canonical activation of NF-kappa-B. Promotes ubiquitination and proteasomal degradation of MAP3K14.

PTMs:

Undergoes 'Lys-48'-linked polyubiquitination, leading to its proteasomal degradation in response to signaling by TNFSF13B, TLR4 or through CD40. 'Lys-48'-linked polyubiquitinated form is deubiquitinated by OTUD7B, preventing TRAF3 proteolysis and over-activation of non-canonical NF-kappa-B. Undergoes 'Lys-63'-linked ubiquitination during early stages of virus infection, and 'Lys-48'-linked ubiquitination during later stages. Undergoes both 'Lys-48'-linked and 'Lys-63'-linked ubiquitination in response to TLR3 and TLR4 signaling. Deubiquitinated by OTUB1, OTUB2 and OTUD5.

Subcellular Location:

Cytoplasm. Endosome. Mitochondrion.
Note: Undergoes endocytosis together with TLR4 upon LPS signaling (By similarity). Associated with mitochondria in response to virus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Homotrimer. Heterotrimer with TRAF2 and TRAF5. Interacts with LTBR/TNFRSF3, TNFRSF4, TNFRSF5/CD40, TNFRSF8/CD30, TNFRSF13C TNFRSF17/BCMA, TLR4 and EDAR. Interacts with MAP3K5, MAP3K14, TRAIP/TRIP, TDP2/TTRAP, TANK/ITRAF and TRAF3IP1. Interaction with TNFRSF5/CD40 is modulated by TANK/ITRAF, which competes for the same binding site. Interacts with TICAM1. Interacts with TRAFD1. Interacts with OTUB1, OTUB2 and OTUD5. Interacts with RNF216, MAVS, OPTN and TBK1. Identified in a complex with TRAF2, MAP3K14 and BIRC3. Interacts with BIRC2 and BIRC3. Upon exposure to bacterial lipopolysaccharide (LPS), recruited to a transient complex containing TLR4, TRAF3, TRAF6, IKBKG, MAP3K7, MYD88, TICAM1, BIRC2, BIRC3 and UBE2N (By similarity). Interacts with Epstein-Barr virus protein LMP1. Interacts (via RING-type zinc finger domain) with SRC. Interacts with CARD14. Interacts (via MATH domain) with PTPN22; the interaction promotes TRAF3 polyubiquitination.

Family&Domains:

The MATH/TRAF domain binds to receptor cytoplasmic domains.

The Ring-type zinc finger domain is required for its function in down-regulation of NFKB2 proteolytic processing.

Belongs to the TNF receptor-associated factor family. A subfamily.

Research Fields

· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > RIG-I-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

References

1). Scavenger receptor A impairs interferon response to HBV infection by limiting TRAF 3 ubiquitination through recruiting OTUB 1. The FEBS Journal, 2020 (PubMed: 31386800) [IF=5.4]

Application: WB    Species: human    Sample: HepG2.2.15 cells

Fig. 7.| Tumor necrosis factor receptor-associated factor 3 is the key element for SRA to limit type I IFN response. HepG2.2.15 cells were transfected with TRAF3 siRNA, together with or without SRA siRNA for 48 h. Western blotting was performed to examine the level of cellular HBcAg (A).

Application: IF/ICC    Species: human    Sample: HepG2.2.15 cells

Fig. 5. |Scavenger receptor A colocalizes and interacts with signaling transducer TRAF3. (B) Colocalization of SRA with TRAF3 in HepG2.2.15 cells. The cells were cultured on glass coverslips and immunostained with antibodies against SRA and TRAF3, respectively,subsequently analyzed by a confocal microscope (Magnification: 6309).

Application: WB    Species: Human    Sample: HepG2.2.15 cells

Fig. 5. Scavenger receptor A colocalizes and interacts with signaling transducer TRAF3. (A) SRA coimmunoprecipitates with TRAF3 in HepG2.2.15 cells. Equal amounts of cell extract were immunoprecipitated with SRA-specific antibody or control IgG. The immune complex was analyzed using anti-TRAF3 antibody (left panel). Besides, TRAF3 was pulled down and analyzed for association with SRA using antiSRA antibody (right panel). Levels of SRA and TRAF3 in the whole cell lysate were also examined. (B) Colocalization of SRA with TRAF3 in HepG2.2.15 cells. The cells were cultured on glass coverslips and immunostained with antibodies against SRA and TRAF3, respectively, subsequently analyzed by a confocal microscope (Magnification: 6309). (C) HepG2 cells were transfected with pHBV1.3 or control plasmid, and equal amounts of protein were used for immunoprecipitation with the SRA-specific antibody. The immunoprecipitates were probed for the presence of TRAF3 and SRA, respectively. (D) TRAF-C domain is essential for the binding of TRAF3 to SRA. HEK293T cells were transfected with HA-tagged SRA and FLAG-tagged full-length TRAF3 or several truncated TRAF3 deletion mutants. Immunoprecipitation was performed using anti-FLAG antibody. The presence of coprecipitated SRA was determined by immunoblotting with the anti-HA antibody. Representative results from three independent experiments are shown.

2). Corilagin Interferes With Toll-Like Receptor 3-Mediated Immune Response in Herpes Simplex Encephalitis. Frontiers in Molecular Neuroscience, 2019 (PubMed: 31080403) [IF=4.8]

Application: WB    Species: mouse    Sample: BV-2 cells

Figure 4.| Lentiviral vector-mediated overexpression of TLR3 in BV-2 cells. The lentivirus (10 MOI) was incubated with the BV-2 cells for 72 h. (A) The expression of GFP was observed with a fluorescence microscope after lentivirus was introduced into the BV-2 cells. (B) The mRNA levels of TLR3 and its downstream molecules were measured by RT-PCR. (C) The protein levels were detected by western blotting. Data are shown as the mean ± SD of three independent experiments of triplicate samples.**P < 0.01 for lentivirus-up vs. normal; *P < 0.05 for lentivirus-up vs. normal (by Student’s t-test).

3). Effects of Co-Administration of Icariin and Panax notoginseng Saponins on Intestinal Microbiota and Hippocampal Protein Expression in a Mouse Model of Alzheimer’s Disease. Neuropsychiatric Disease and Treatment, 2022 (PubMed: 33061388) [IF=3.2]

Application: WB    Species: Mouse    Sample:

Figure 7 Treatment with ICA and PNS reduced MIPT3 and increased Oasl1 and TCHP protein levels. N=6 in each group. *P < 0.05 compared the control group, #P < 0.05 compared with the AD group.

4). The intervention mechanism of emodin on TLR3 pathway in the process of central nervous system injury caused by herpes virus infection. NEUROLOGICAL RESEARCH, 2021 (PubMed: 33274693) [IF=1.9]

Application: WB    Species: Mice    Sample: brain tissues

Figure 4. The protein expression of TLR3 and its downstream protein in brain tissues of mice.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.